Please assess the completion status of the following clinical trial:

Trial Title: A Study to Assess if Mirikizumab is Effective and Safe Compared to Secukinumab and Placebo in Moderate to Severe Plaque Psoriasis (OASIS-2)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Participant must have chronic plaque psoriasis for at least 6 months.~Exclusion Criteria:~* Participant must not be breastfeeding or nursing woman.~* Participant must not have had serious, opportunistic, or chronic/recurring infection within 3 months.~* Participant must not have received a Bacillus Calmette-Guerin (BCG) vaccination within 12 months or received live vaccine(s) (including attenuated live vaccines) within 12 weeks of baseline or intend to receive either during the study.~* Participant must not have any other skin conditions (excluding psoriasis).~* Participant must not have previous exposure to Cosentyx and any other biologic therapy targeting IL-17 (including Taltz).~* Participant must not have received anti-tumor necrosis factor (TNF) biologics within 8 weeks.~* Participant must not have previous exposure to any biologic therapy targeting IL-23 (including Stelara).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 250mg Q4W/250mg Q8W Mirikizumab (Type: EXPERIMENTAL): Participants received 250 Milligrams (mg) Mirikizumab once every four weeks (Q4W) by subcutaneous injection during blinded induction period followed by 250mg Mirikizumab once every eight weeks (Q8W) in maintenance period. Participants received matching placebo to blind Secukinumab.
- 250mg Q4W/125mg Q8W Mirikizumab (Type: EXPERIMENTAL): Participants received 250mg Mirikizumab once every four weeks (Q4W) by subcutaneous injection during blinded induction period followed by 125mg Mirikizumab once every eight weeks (Q8W) in maintenance period. Participants received matching placebo to blind Secukinumab.
- Placebo/250mg Mirikizumab (Type: EXPERIMENTAL): Participants received matching placebo at weeks 0, 1, 2, 3, 4, 8, and 12 by subcutaneous injection during blinded induction period followed by 250mg Mirikizumab Q4W from week 16 to 32 followed by 250mg Mirikizumab Q8W from week 32 to 48 in maintenance period. Participants received matching placebo to blind Secukinumab.
- 300mg Secukinumab (Type: ACTIVE_COMPARATOR): Participants received 300mg Secukinumab at weeks 0, 1, 2, 3, 4, 8, and 12 by subcutaneous injection during induction period followed by 300mg Secukinumab Q4W from week 16 to 52 in maintenance period.
- Japan GPP/EP (Type: EXPERIMENTAL): Participants received 250mg Mirikizumab Q4W in induction period followed by 250mg Q8W in maintenance period by subcutaneous injection.

Based on this trial design, predict the completion outcome and termination type (if applicable).